Trump’s Transparent Hospital Pricing Pays Off for Industry — But Not So Much for Patients

“We’re going to post that, all the prices for everything,” Health and Human Services Secretary Robert F. Kennedy Jr. declared at a recent event held by the conservative Heritage Foundation in Washington. It’s a bold-sounding promise, and a familiar one; politicians from both parties have been repeating it for years now. Both Trump administrations — and the Biden administration in between — have taken whacks at making medical prices more accessible,…

Read More

Should Drug Companies Be Advertising to Consumers?

Tamar Abrams had a lousy couple of years in 2022 and ’23. Both her parents died; a relationship ended; she retired from communications consulting. She moved from Arlington, Virginia, to Warren, Rhode Island, where she knew all of two people. “I was kind of a mess,” recalled Abrams, 69. Trying to cope, “I was eating…

Read More

Links

FDA reverses its decision and will now review the Moderna flu vaccine.Could Australia be a model for FDA reform?“Pharma signals it’s done negotiating”Giant viruses.Hairy ball theorem.

Read More

Can We Ride the GenAI Wave Without Getting Subsumed by It?

By DAVID SHAYWITZ “There are decades where nothing happens; and there are weeks where decades happen,” said Lenin, probably never.  It’s also a remarkably apt characterization of the last year in generative AI (genAI) — the last week in particular — which has seen the AI landscape shift so dramatically that even skeptics are now updating…

Read More

Decoding the PBM Reform Provisions of the 2026 Consolidated Appropriations Act

After years of legislative debate, Congress has formally codified PBM reform into federal statute. Tucked within the Consolidated Appropriations Act, 2026 (H.R. 7148), signed on February 3, 2026 are structural mandates that will reshape Pharmacy Benefit Manager (PBM) operations in Medicare Part D and the commercial sector by 2028. The legislation targets three primary pillars:…

Read More